Appointment includes a 1:1 consultation with Stephanie Thompson, DNP, APRN and 4 weeks worth of medication sent to your home. Your current dose will be listed on your prescription.
$425/month
Tirzepatide is a dual-acting peptide that activates both GLP-1 and GIP receptors to enhance metabolic pathways in the body. This unique mechanism not only increases blood sugar metabolism and reduces appetite but also offers superior weight loss and blood sugar control compared to single-receptor medications like Semaglutide. While Semaglutide activates only the GLP-1 receptor, Tirzepatide's dual activation provides a more comprehensive approach to weight loss and blood sugar control, leading to enhanced weight loss and better blood sugar management.
Tirzepatide is administered as a weekly injection that can be self-administered. The Food and Drug Administration (FDA) has approved Tirzepatide for the treatment of type 2 diabetes and weight management. This dual-action medication is especially effective for those seeking to improve their metabolic health. By combining the effects of two hormone receptors, GLP-1 and GIP, Tirzepatide reduces appetite, slows down food digestion, helps you feel fuller for longer, enhances insulin secretion, and improves insulin sensitivity, leading to better blood sugar control.
Possible side effects of Tirzepatide include nausea, stomach pain, diarrhea, changes in appetite, and mild gastrointestinal issues. For a full list of side effects, please scan the QR code or visit our website. To minimize side effects, we start you at a lower dose of Tirzepatide for the first month to allow your body to get used to it. The dosage is typically increased incrementally in the second and third months, although everyone’s response to the medication can vary. Our goal is for you to lose a few pounds a week with minimal side effects.
For Patients with:
•A body mass index (BMI) of 30 kg/m2 or greater
•A BMI of 27 kg/m2 or greater with at least one weight-related ailment such as type 2 diabetes, hypertension, sleep apnea, or others.